Roche agreed to acquire Kapa Biosystems, which focuses on developing technologies for optimizing enzymes for next-generation sequencing (NGS), as well as for polymerase chain reaction (PCR) and real-time PCR applications.
According to Roche, Kapa’s protein engineering technology is customizable and allows for the generation and screening of large numbers of enzyme variants.
“Tailored enzymes with improved performance for specific applications can be rapidly selected, expediting product development timelines,” explained Roland Diggelmann, COO, Roche Diagnostics. “Kapa`s impressive portfolio of NGS reagents includes enzymes such as novel DNA polymerases, with the potential to improve the performance of the entire sequencing workflow.
Diggelmann added that Kapa’s technology and products complement Roche’s current expertise and offerings such as of target enrichment products for NGS.